Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 11/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 11/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL238507 | 0.94 | LPL (0.44) | LPLLIPGESR2OPRM1CA1 | |
| SCHEMBL12077932 | 0.94 | LPL (0.44) | LPLLIPGESR2OPRM1CA1 | |
| SCHEMBL3262915 | 0.91 | ESR2 (0.42) | LPLLIPGESR2OPRM1CA1 | |
| SCHEMBL30900711 | 0.90 | ESR2 (0.41) | LPLLIPGESR2OPRM1CA1 | |
| SCHEMBL23571317 | 0.87 | LPL (0.40) | LPLLIPGESR2OPRM1 | |
| SCHEMBL31353318 | 0.85 | ESR2 (0.40) | LPLLIPGESR2CA1CA2 | |
| SCHEMBL13778138 | 0.85 | OPRM1 (0.43) | LPLLIPGESR2OPRM1 | |
| SCHEMBL17129428 | 0.84 | DGAT1 (0.47) | LPLLIPGESR2CA1CA2 | |
| SCHEMBL234668 | 0.82 | ESR2 (0.40) | LPLLIPGESR2CA1CA2 | |
| SCHEMBL2588245 | 0.81 | LPL (0.43) | LPLLIPGESR2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103464-A1 | CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYL-PYRIDINE DERIVATIVES | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2026-04-16 | — | — | US | disclosed |
| US-12595266-B2 | Pesticidally active heterocyclic derivatives with sulfur containing substituents | SYNGENTA CROP PROTECTION AG (CH) | 2026-04-07 | — | — | US | disclosed |
| US-12435083-B2 | Cyclopropyl-(hetero)aryl-substituted ethylsulphonyl-pyridine derivatives | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-10-07 | — | — | US | disclosed |
| EP-4615523-A1 | COMPOUNDS AND THEIR USE | KING'S COLLEGE LONDON (GB) | 2025-09-17 | — | — | EP | disclosed |
| US-20250163068-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2025-05-22 | — | — | US | disclosed |
| WO-2024175557-A1 | CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYL-SULFOXIME-PYRIDINE DERIVATIVES | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2024-08-29 | — | — | WO | disclosed |
| CN-118355004-A | Cyclopropyl- (heteroaryl) -substituted ethylsulfonyl-pyridine derivatives | 勃林格殷格翰动物保健有限公司 | 2024-07-16 | — | — | CN | disclosed |
| EP-4397308-A2 | COMPOUNDS AND THEIR METHODS OFUSE | Praxis Precision Medicines, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20240190867-A1 | HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-13 | — | — | US | disclosed |
| WO-2024100095-A1 | COMPOUNDS AND THEIR USE | KING’S COLLEGE LONDON (GB) | 2024-05-16 | — | — | WO | disclosed |
| US-8058300-B2 | Polycyclic antagonists of lysophosphatidic acid receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2366699-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2011-09-21 | — | — | EP | disclosed |
| WO-2010141768-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141768-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20100311799-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| WO-2010141761-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| WO-2010038465-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | 旭化成ファーマ株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010010184-A1 | [1, 2, 4] TRIAZOLO [1, 5-A] PYRIDINES AS JAK INHIBITORS | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190867-A1 | HETEROCYCLE DERIVATIVES AS PESTICIDES | DDT, CBR3, CBR1 | LPL 4310/4885LIPG 4673/4885ESR2 3476/4885 |
| US-12595266-B2 | Pesticidally active heterocyclic derivatives with sulfur containing substituents | CBR3, CBR1, CYCS | LPL 4169/4885LIPG 4598/4885ESR2 4566/4885 |
| US-20250163068-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | LPL 2581/4885LIPG 2434/4885ESR2 2597/4885 |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | LPL 3942/4885LIPG 3515/4885ESR2 1734/4885 |
| US-20100311799-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | LPL 168/4885LIPG 174/4885ESR2 875/4885 |
| US-12435083-B2 | Cyclopropyl-(hetero)aryl-substituted ethylsulphonyl-pyridine derivatives | CYCS, CYP2E1, CYP1A1 | LPL 4533/4885LIPG 4842/4885ESR2 1431/4885 |
| US-20260103464-A1 | CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYL-PYRIDINE DERIVATIVES | CBR3, CYCS, CBR1 | LPL 3988/4885LIPG 4310/4885ESR2 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.